Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (DE:08HH)
FRANKFURT:08HH
Total Valuation
Shanghai Fosun Pharmaceutical (Group) Co has a market cap or net worth of €6.91B. The enterprise value is €88.21B.
Market Cap€6.91B
Enterprise Value€88.21B
Share Statistics
Shanghai Fosun Pharmaceutical (Group) Co has 551,940,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding551,940,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shanghai Fosun Pharmaceutical (Group) Co’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 2.00%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)2.00%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee996.73K
Profits Per Employee104.74K
Employee Count40,557
Asset Turnover0.34
Inventory Turnover3.24
Valuation Ratios
The current PE Ratio of Shanghai Fosun Pharmaceutical (Group) Co is 16.7. Shanghai Fosun Pharmaceutical (Group) Co’s PEG ratio is 0.74.
PE Ratio16.7
PS Ratio1.15
PB Ratio0.95
Price to Fair Value0.95
Price to FCF60.76
Price to Operating Cash Flow9.74
PEG Ratio0.74
Income Statement
In the last 12 months, Shanghai Fosun Pharmaceutical (Group) Co had revenue of 40.42B and earned 3.28B in profits. Earnings per share was 1.24.
Revenue40.42B
Gross Profit20.16B
Operating Income2.54B
Pretax Income4.98B
Net Income3.28B
EBITDA6.16B
Earnings Per Share (EPS)1.24
Cash Flow
In the last 12 months, operating cash flow was 4.06B and capital expenditures -3.33B, giving a free cash flow of 731.79M billion.
Operating Cash Flow4.06B
Free Cash Flow731.79M
Free Cash Flow per Share1.33
Dividends & Yields
Shanghai Fosun Pharmaceutical (Group) Co pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change-4.18%
50-Day Moving Average2.04
200-Day Moving Average2.31
Relative Strength Index (RSI)33.61
Average Volume (3m)1.21K
Important Dates
Shanghai Fosun Pharmaceutical (Group) Co upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateApr 28, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Shanghai Fosun Pharmaceutical (Group) Co as a current ratio of 0.93, with Debt / Equity ratio of 81.20%
Current Ratio0.93
Quick Ratio0.76
Debt to Market Cap0.72
Net Debt to EBITDA3.82
Interest Coverage Ratio2.06
Taxes
In the past 12 months, Shanghai Fosun Pharmaceutical (Group) Co has paid 841.69M in taxes.
Income Tax841.69M
Effective Tax Rate0.17
Enterprise Valuation
Shanghai Fosun Pharmaceutical (Group) Co EV to EBITDA ratio is 11.36, with an EV/FCF ratio of 91.55.
EV to Sales1.73
EV to EBITDA11.36
EV to Free Cash Flow91.55
EV to Operating Cash Flow13.43
Balance Sheet
Shanghai Fosun Pharmaceutical (Group) Co has €15.29B in cash and marketable securities with €31.86B in debt, giving a net cash position of -€16.57B billion.
Cash & Marketable Securities€15.29B
Total Debt€31.86B
Net Cash-€16.57B
Net Cash Per Share-€30.02
Tangible Book Value Per Share€12.50
Margins
Gross margin is 49.44%, with operating margin of 6.27%, and net profit margin of 8.12%.
Gross Margin49.44%
Operating Margin6.27%
Pretax Margin12.32%
Net Profit Margin8.12%
EBITDA Margin15.25%
EBIT Margin6.27%
Analyst Forecast
The average price target for Shanghai Fosun Pharmaceutical (Group) Co is €3.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€3.45
Price Target Upside43.89% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-2.79%
EPS Growth Forecast17.57%